We recently published an article titled These 10 Firms Led This Week’s Rally. In this article, we are going to take a look at ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

Fintel reports that on January 7, 2025, William Blair downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Outperform to Market Perform. Analyst Price Forecast Suggests 14.20% Downside As ...

Inari shareholders are getting a fair price ... with a primary focus on stroke and aneurysm treatment including coils, catheters, microcatheters, stents, and mechanical thrombectomy devices.

Inari Medical (NARI – Research Report) received a Hold rating and price target from William Blair analyst Margaret Kaczor today. The ...

Inari Medical, which has a market value approaching $3 billion, is expected to enhance Stryker's portfolio by expanding its treatment options for venous thromboembolism, a condition characterized ...

Inari Medical was founded in 2011 and focuses on the treatment of venous thromboembolism, which impacts up to 900,000 people per year in the United States. “With Stryker’s capabilities and ...

However, new therapies like ClotTriever and FlowTriever products are demonstrating rising adoption as they lead to lower treatment-related risks. Inari focuses on establishing its treatments as the ...

Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: ...

Medtronic (NYSE: MDT) announced today that it entered into an exclusive U.S. distribution agreement with Contego Medical.

After years of being consumed by the paclitaxel mortality debate, the endovascular field saw new advances in drug and device therapies in 2024, as well as the first treatment for below ... with the ...

AngioDynamics' fiscal Q2'25 results exceeded expectations, with Med Tech growing 25% and delivering better gross margins. See ...